Eurofins Viracor ExPeCT™ CAR-T multiplexed quantitative real-time PCR (qPCR) assay provides a powerful diagnostic tool to monitor and optimize CAR-T therapy involving patients with pre-B cell acute lymphoblastic leukemia and B cell lymphomas
LENEXA, Kan., Feb. 16, 2023 /PRNewswire/ -- Eurofins Viracor LLC, a leader in testing for infectious disease, immunology, and allergy, today announced the launch of a ground-breaking test that can assess the expansion and persistence of Chimeric Antigen Receptor T-Cell (CAR-T) therapy in patients with pre-B cell acute lymphoblastic leukemia and B cell lymphomas.
The test, based on a method developed by Eurofins Viracor, is designed to help clinicians better understand how CAR-T therapy is performing for their patients. CAR-T therapy is a revolutionary form of immunotherapy that uses genetically engineered T-cells to attack cancer cells and has shown promising results in treating a variety of cancers.
Research has demonstrated that the persistence and expansion of CAR-T therapy are important indicators of how long the therapy is likely to remain effective in the patient. The test is designed to provide clinicians with an accurate and comprehensive assessment of the CAR-T cell population in the patient's body and may offer insights to therapy effectiveness.
The launch of this test marks an important step forward in the evaluation and management of CAR-T therapy in cancer patients. It is expected to be a valuable tool in helping clinicians to make more informed decisions about the best course of treatment for their patients.
For more information, please visit https://www.eurofins-viracor.com/clinical/our-testing/car-t
About Eurofins Viracor
Eurofins Viracor LLC has over 30 years of diagnostic expertise in infectious disease, immunology and allergy testing for immunocompromised and critical patients. Eurofins Viracor is a subsidiary of Eurofins Scientific (EUFI.PA), a global leader in bio-analytical testing, and one of the world leaders in genomic services. For more information, please visit https://www.eurofins.com/ and https://www.eurofins-viracor.com/clinical/our-testing/car-t
About the Eurofins Group – the global leader in bio-analysis
Eurofins is Testing for Life. With over 61,000 staff across a network of 940 laboratories in 59 countries, Eurofins' companies offer a portfolio of over 200,000 analytical methods.
Eurofins Shares are listed on Euronext Paris Stock Exchange.
SOURCE Eurofins Viracor LLC
Share this article